Neogen Corporation (NEOG) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with improved margins and EBITDA, alongside optimistic guidance. The Q&A section highlights effective management and strategic initiatives, such as the Petrifilm manufacturing process and commercial organization changes. Despite some conservative guidance and ongoing challenges, the overall sentiment is positive, with raised guidance and customer confidence in key product lines. Given the market cap, the stock price is likely to react positively, but not overwhelmingly so.
Key Financial Performance
Total Second Quarter Revenues $224.7 million, increasing 2.9% on a core basis year-over-year. Foreign currency added 0.9%, while divestitures and discontinued products were a headwind of 6.6% compared to the prior year. The impact from divestitures was due to the sale of the Cleaners and Disinfectants business.
Food Safety Segment Revenues $165.6 million, with core revenue growth of 4.1% year-over-year. Growth was driven by indicator testing and culture media product category, sample collection, and Petrifilm recovery. Double-digit growth in pathogens was offset by a decline in natural toxins.
Animal Safety Segment Revenues $59.1 million, with core revenue growth approximately flat year-over-year. Growth in biosecurity products was offset by declines in veterinary instruments and life sciences product categories.
Gross Margin 47.5%, a sequential improvement of 210 basis points from the first quarter. Excluding integration-related and restructuring costs, gross margin was 50.3%. Improvement was due to volume and lower tariff costs.
Adjusted EBITDA $48.7 million, representing a margin of 21.7%, an improvement of 470 basis points from the first quarter. Improvement was driven by higher gross margin and headcount reduction.
Adjusted Net Income $22.6 million, compared to $9.4 million in the prior quarter. The increase was primarily due to higher adjusted EBITDA.
Free Cash Flow $7.8 million, an improvement of $20.9 million from Q1 due to lower CapEx and improved trade working capital efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Sample collection product line: Progress made with expectations to contribute positively to gross profit in the second half of the fiscal year.
Petrifilm: Integration on track for fiscal 2027 with successful production testing and initial product validation.
Food Safety: Strong growth in indicator testing, culture media, and pathogen detection products. Over 75% of customers purchase multiple product categories, with initiatives to increase this percentage.
Animal Safety: Flat core revenue growth with solid performance in biosecurity products and challenges in veterinary instruments and life sciences categories.
Cost structure improvements: Implemented changes expected to save $20 million annually.
Adjusted EBITDA margin: Improved by nearly 500 basis points sequentially, driven by cost actions and operational efficiencies.
Inventory management: Focus on reducing inventory write-offs and improving scrap levels over multiple quarters.
Leadership changes: New CFO, Chief Commercial Officer, and other senior leaders appointed to drive transformation and operational excellence.
Genomics business divestiture: Process underway with expected announcement in Q4 FY 2026 to simplify business and reduce debt.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic Headwinds: The company is facing macroeconomic challenges, including inflationary cost pressures, which have led to disruptions at the customer level, reduced food production volumes, major plant closures, and food producer bankruptcies.
Execution Challenges: The company acknowledges past execution-related headwinds and is in the early stages of addressing these issues through operational and leadership changes.
Inventory Management: Elevated levels of inventory write-offs were noted, and the company is undergoing a multi-quarter process to return to normal levels of scrap and improve inventory management.
Animal Safety Market Decline: The production animal herds in the U.S. have declined to record lows, impacting the Animal Safety segment. While forecasts suggest a reversal, the company remains cautious.
Integration of Petrifilm: The integration of Petrifilm is ongoing, with production testing and product validation still in progress. Delays or issues in this process could impact timelines and operational efficiency.
Divestiture of Genomics Business: The planned divestiture of the genomics business is still in progress, and its timing is uncertain. This could impact the company’s ability to reduce debt and simplify operations as planned.
End Market Weakness: Lingering weakness in end markets, particularly in food safety and animal safety, continues to pose challenges for revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company has raised its full-year revenue guidance for fiscal 2026 to a range of $845 million to $855 million, reflecting better-than-expected second-quarter performance.
Adjusted EBITDA: The adjusted EBITDA for fiscal 2026 is expected to be approximately $175 million, with a cautious approach to the second half of the year due to lingering market weaknesses.
Capital Expenditures: Routine capital expenditures are expected to normalize to 3%-4% of revenue starting in late fiscal year 2026, with total CapEx for the year projected at approximately $50 million.
Free Cash Flow: Free cash flow is expected to remain positive for fiscal 2026, supported by lower CapEx and improved working capital efficiency.
Market Trends and Recovery: While macroeconomic headwinds persist, some challenges are expected to abate as the company transitions into fiscal year 2027 and beyond. For example, production animal herds in the U.S. are forecasted to recover next year due to record beef prices.
Operational Efficiency: The company expects continued improvement in production efficiency, particularly in the sample collection product line, which is anticipated to contribute positively to gross profit in the second half of fiscal 2026.
Divestitures: The company plans to divest its global genomics business, with an announcement expected in the fourth quarter of fiscal 2026. Proceeds will be used for debt reduction and to simplify the business.
Petrifilm Integration: The integration of Petrifilm remains on track for completion by the second quarter of fiscal 2027, with production testing and product validation progressing well.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss the new management team, what you look for in team members, and how long it will take for them to gel and make a difference?
A:The company has attracted top-tier talent with experience in diagnostics or life sciences, particularly those who have managed global businesses and can implement global processes. The onboarding process is robust, and the team is already hitting the ground running. The focus remains on driving top-line growth, optimizing growth, and mastering fundamentals.
Q:What was the headwind to margins from sample handling, and what are the expectations for margins once improvements are made?
A:Sample collection has been a challenge, but improvements are being made in pricing, efficiency, and reducing temporary labor and scrap. The product is expected to return to profitability in the second half of the year. The negative impact on margins has been decreasing, with $10 million in Q4, $6 million in Q1, and $3 million in Q2.
Q:Why hasn’t the implied H2 growth or margin been higher following a strong quarter? Is this due to conservatism?
A:The guidance reflects a prudent approach to achieving sustained and predictable performance. The new team is settling in, and the focus is on building credibility with investors. While Q2 was strong, it is only one data point, and macroeconomic uncertainties remain. The company has raised its guidance to reflect positive growth for the year.
Q:Were there any one-time revenue tailwinds in the quarter, and how should recurring adjustments be considered for the rest of the year?
A:There was a $2 million insecticide tailwind in the Animal Safety segment, but this was the only notable one-time factor. The company is focusing on driving commercial excellence and key products like Petrifilm, pathogens, and allergens, which contributed to organic growth.
Q:What changes in the commercial organization have led to improved forecasting and raised guidance?
A:The company has implemented a weekly forecasting process involving sales leaders and supporting functions to review risks, opportunities, and targeted accounts. The focus is on enabling the commercial team and driving customer-centricity. This approach has resonated with the organization and contributed to improved performance.
Q:What gives confidence in the Petrifilm manufacturing process and its timeline?
A:The company has a detailed plan for the Petrifilm manufacturing process, which remains on track for the November 2027 timeline. Production testing and initial product validation have gone well, demonstrating the ability to manufacture Petrifilm on new equipment. The project is a top priority with dedicated resources.
Q:How much of the growth in indicator testing and culture media was volume-driven versus price-driven?
A:Most of the growth was organic and volume-driven, with some recovery from inventory corrections in major distributors. The Petrifilm market remains healthy, and pathogens and allergens have also contributed to growth. Overall, growth was more volume-driven than price-driven.
Q:What are the updated assumptions for the 2026 growth rate for Petrifilm, and is there pricing power in the market?
A:There is pricing opportunity, particularly with new contracts and inflationary adjustments. The company expects the Petrifilm product to perform consistently for the remainder of the year, similar to Q2.
Q:What feedback has been received from customers regarding supply issues and the company’s role in their Food Safety programs?
A:Customers view Neogen as a vital partner in their Food Safety programs and are rooting for the company’s success despite some frustrations with supply issues. Neogen is seen as the expert in Food Safety, and customers rely on the company to fill gaps in training and knowledge.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact timeline for achieving full profitability in sample handling and the precise impact of macroeconomic uncertainties on future performance. Additionally, while they mentioned pricing opportunities for Petrifilm, they did not provide detailed assumptions for the 2026 growth rate.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Abbott
Chief
Head
Neogen
Officer
Senior Vice
Vice President
allergen decline
approach
backdrop
category allergen
category sale
collection product
confidence ability
customer
decline toxin
detail
detection product
divestiture
excellence
genomics decline
improvement basis
industry
investor
margin improvement
outlook
parallel
plate
producer
record
region core
region digit
return core
scale
solution
stage
summer
team
timing
track
transformation
trend
validation
NEOG Transcript
Neogen Corporation (NEOG) Q2 2026 Earnings Call Transcript
Positive1-8
The earnings call reveals strong financial performance with improved margins and EBITDA, alongside optimistic guidance. The Q&A section highlights effective management and strategic initiatives, such as the Petrifilm manufacturing process and commercial organization changes. Despite some conservative guidance and ongoing challenges, the overall sentiment is positive, with raised guidance and customer confidence in key product lines. Given the market cap, the stock price is likely to react positively, but not overwhelmingly so.
Neogen Corporation (NEOG) Q1 2026 Earnings Call Transcript
Unknown10-9
The earnings call summary presents a mixed picture: while there are positive aspects like the strong performance of Petrifilm and expected EBITDA margin improvement, there are concerns about supply challenges, margin pressures, and a lack of raised guidance despite revenue beats. The Q&A section reveals management's cautious stance, especially regarding early-year uncertainties and execution challenges. These factors, combined with the company's mid-sized market cap, suggest a neutral stock price movement in the short term.
Neogen Corporation (NEOG) Q4 2025 Earnings Call Transcript
Unknown7-29
The earnings call revealed declines in core revenues across segments, a significant goodwill impairment, and a lowered EBITDA. Despite some positive updates, like pathogen testing growth and reduced CapEx, the overall sentiment is negative due to the weak financial performance and market outlook. The Q&A highlighted concerns about tariffs and macroeconomic pressures, further dampening investor sentiment. With a market cap of $3.45 billion, the stock is likely to experience a negative reaction, falling within the -2% to -8% range over the next two weeks.
Neogen Corporation (NASDAQ:NEOG) Q3 2025 Earnings Call Transcript
Unknown4-10
The earnings call reveals several concerning factors: missed EPS expectations, downward revenue and EBITDA guidance, and significant macroeconomic and tariff headwinds. Despite some positive aspects like restructuring efforts and U.S. food safety growth, the lack of a share repurchase program and unclear management responses in the Q&A contribute to a negative sentiment. The company's market cap suggests a moderate reaction, leading to a predicted stock price decline of -2% to -8% over the next two weeks.
NEOG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
